WAVE LIFE SCIENCES LTD. Accrued Liabilities, Current
WAVE LIFE SCIENCES LTD. (WVE) had Accrued Liabilities, Current of $5.18 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Accrued Liabilities, Current $5.18M.
- 2026-03-31: Accrued Liabilities, Current $4.85M.
- 2025-12-31: Accrued Liabilities, Current $7.31M.
- 2025-09-30: Accrued Liabilities, Current $4.59M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $5.18M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $4.85M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $7.31M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $4.59M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.18M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $1.72M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $4.55M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.83M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.21M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.75M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $1.77M 10-K · filed 2025-03-04 |
| 2023-09-30 | $3.08M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.66M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $2.13M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $3.52M 10-K · filed 2024-03-06 |
| 2022-09-30 | $1.91M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.47M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.15M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.57M 10-K · filed 2023-03-23 |
| 2021-09-30 | $3.38M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $3.23M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $2.14M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.20M 10-Q · filed 2020-11-09 |
| 2019-12-31 | $5.03M 10-K · filed 2021-03-04 |
| 2018-12-31 | $5.50M 10-K · filed 2020-03-02 |
| 2017-12-31 | $3.28M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |